Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

[Epidermic growth factor receptor (EGFR) in glioblastomas: the mechanism of tumorigenesis and its role as a therapeutic target].

Zahonero C, Sepúlveda JM, Sánchez-Gómez P.

Rev Neurol. 2015 Jul 16;61(2):85-93. Review. Spanish.

PMID:
26156444
2.

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.

Zahonero C, Aguilera P, Ramírez-Castillejo C, Pajares M, Bolós MV, Cantero D, Perez-Nuñez A, Hernández-Laín A, Sánchez-Gómez P, Sepúlveda JM.

Mol Cancer Ther. 2015 Jul;14(7):1548-58. doi: 10.1158/1535-7163.MCT-14-0736. Epub 2015 May 4.

3.

Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma.

González-Gómez P, Crecente-Campo J, Zahonero C, de la Fuente M, Hernández-Laín A, Mira H, Sánchez-Gómez P, Garcia-Fuentes M.

Oncotarget. 2015 May 10;6(13):10950-63.

4.

DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.

Fernández-Martínez P, Zahonero C, Sánchez-Gómez P.

Mol Cell Oncol. 2015 Jan 30;2(1):e970048. doi: 10.4161/23723548.2014.970048. eCollection 2015 Jan-Mar. Review.

5.

EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.

Zahonero C, Sánchez-Gómez P.

Cell Mol Life Sci. 2014 Sep;71(18):3465-88. doi: 10.1007/s00018-014-1608-1. Epub 2014 Mar 27. Review.

PMID:
24671641
6.

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.

Pozo N, Zahonero C, Fernández P, Liñares JM, Ayuso A, Hagiwara M, Pérez A, Ricoy JR, Hernández-Laín A, Sepúlveda JM, Sánchez-Gómez P.

J Clin Invest. 2013 Jun;123(6):2475-87. doi: 10.1172/JCI63623. Epub 2013 May 1.

7.

[Demographic variables, hemodialysis and tendency to depression].

Zahonero C, Polaino Lorente A.

Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1986 Jan-Feb;14(1):59-64. Spanish. No abstract available.

PMID:
3716908

Supplemental Content

Loading ...
Support Center